The Atif J. Khan Laboratory for Optimizing Breast Cancer Outcomes and Life Expectancy (LOBULE): Publications

The Atif J. Khan Laboratory for Optimizing Breast Cancer Outcomes and Life Expectancy (LOBULE)
Publications
Members

The Atif J. Khan Laboratory for Optimizing Breast Cancer Outcomes and Life Expectancy (LOBULE): Publications

Share
Share

Haffty BG, Harrold E, Khan A, Pathare P, Ward BA, Matloff E, Alvarez-Franco M, Bale AE. (2002). Conservatively Managed Breast Cancer in Young Women: Outcome as a Function of BRCA 1/2 Status.  Lancet, 27;359(9316), 1471-7.  

Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG.  (2011). Riluzole Enhances Ionizing Radiation-induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor In Vitro and In Vivo.  Clinical Cancer Research, 17(7), 1807-14. PMCID: PMC3070864

Wall BA, Wangari-Talbot J, Shin SS, Schiff D, Sierra J, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S. (2014) Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res. 27(2):263-74. PMCID: PMC3947419

Wall BA, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S. (2015) Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells. Pigment Cell Melanoma Res. 28(1):105-9. PMCID: PMC5661976

Khan AJ, La Cava S, Mehta M, Schiff D, Thandoni A, Jhawar SR, Danish S, Haffty BG, Chen S. (2019)The Glutamate Release Inhibitor Riluzole Increases DNA Damage and Enhances Cytotoxicity in Human Glioma Cells, In vitro and In vivo. Oncotarget. 10(29): 2824-2834.   PMCID: PMC6497458

Khan AJ, Poppe M, Goyal S, Kokeny KE, Kearney T, Kirstein L, Toppmeyer D, Moore DF, Chen C, Gaffney DK, Haffty BG. (2017) Hypofractionated Post-Mastectomy Radiation Therapy is Safe and Effective: First Results from a Prospective Phase II Trial.  J Clin Oncol.  35 (18):2037-2043.  doi: 10.1200/JCO.2016.70.7158. PMCID: PMC5476174.

Khan AJ, Chen P, Yashar C, Poppe M, Li L, Yehia ZA, Vicini FA, Moore D, Dale R, Arthur D, Shah C, Haffty BG, Kuske R. (2019) Three-fraction Accelerated Partial Breast Irradiation (APBI) Delivered with Brachytherapy Applicators is Feasible and Safe: First Results from the Triumph-T Trial.  Int J Radiat Oncol Biol Phys.  104(1):67-74. doi: 10.1016/j.ijrobp.2018.12.050. PMCID: PMC7373303.

Khan AJ, Misenko SM, Thandoni A, Schiff D, Jhawar S, Bunting SF, Haffty BG.  (2018) VX-984 is a selective inhibitor of non-homologous end joining with possible preferential activity in transformed cells.  Oncotarget 9(40):25833-25841. doi: 10.18632/oncotarget.25383. PMCID: PMC5995231.

Li J, Hubisz MJ, Earlie EM, Duran MA, Hong C, Varela AA, Lettera E, Deyell M, Tavora B, Havel JJ, Phyu SM, Amin AD, Budre K, Kamiya E, Cavallo JA, Garris C, Powell S, Reis-Filho JS, Wen H, Bettigole S, Khan AJ, Izar B, Parkes EE, Laughney AM, Bakhoum SF. Non-cell-autonomous cancer progression from chromosomal instability. Nature. 2023 Aug;620(7976):1080-1088. doi: 10.1038/s41586-023-06464-z. Epub 2023 Aug 23. PubMed PMID: 37612508; PubMed Central PMCID: PMC10468402.